Three Prescription Options for Uncomplicated Vulvovaginal Candidiasis
For a healthy 32-year-old woman with uncomplicated vulvovaginal candidiasis, prescribe oral fluconazole 150 mg as a single dose first-line, with terconazole 0.8% cream 5g intravaginally daily for 3 days as second-line, and miconazole 1200 mg vaginal suppository as a single dose third-line option. 1, 2
First-Line: Oral Fluconazole
- Fluconazole 150 mg orally, single dose
- This is the most convenient option with equivalent efficacy to topical agents 2
- Strong recommendation with high-quality evidence from both CDC 2021 and IDSA 2016 guidelines
- Patient preference typically favors oral therapy over intravaginal formulations
- No difference in clinical outcomes compared to topical azoles
Second-Line: Terconazole Cream (Prescription Pessary)
- Terconazole 0.8% cream, 5g intravaginally daily for 3 days
- This is a prescription-strength intravaginal option when oral therapy is unavailable or contraindicated 1
- Alternative shorter course: Terconazole 80 mg vaginal suppository, one daily for 3 days
- Terconazole may have advantages in certain non-albicans species compared to other azoles
- Provides direct local therapy with minimal systemic absorption
Third-Line: Miconazole Suppository (Over-the-Counter Pessary)
- Miconazole 1200 mg vaginal suppository, single dose
- Available over-the-counter, making it highly accessible 1
- Single-dose convenience comparable to oral fluconazole
- Alternative: Miconazole 200 mg suppository daily for 3 days if the 1200 mg formulation is unavailable
- Other OTC options include clotrimazole or tioconazole formulations with similar efficacy
Key Clinical Considerations
When to use topical over oral:
- Pregnancy (fluconazole contraindicated)
- Patient preference for local therapy
- Concerns about drug interactions with oral azoles
- First trimester pregnancy requires topical therapy only
Important caveats:
- All these recommendations assume uncomplicated VVC (mild-to-moderate symptoms, sporadic occurrence, likely C. albicans, immunocompetent host) 2
- If symptoms are severe, consider fluconazole 150 mg every 72 hours for 2-3 doses instead 2
- No single topical agent is superior to another—choice depends on availability, cost, and patient preference 1, 2
- Confirm diagnosis with microscopy or culture when possible, as clinical diagnosis alone has poor sensitivity 1
Red flags requiring different management:
- Recurrent VVC (≥4 episodes/year) requires extended maintenance therapy
- Suspected non-albicans species (especially C. glabrata) may need boric acid 600 mg intravaginally daily for 14 days 2
- Immunocompromised patients require longer treatment courses
The 2022 CDC guidelines 1 provide the most current framework, confirming that both oral and topical azoles remain equally effective first-line options with strong evidence, allowing flexibility based on availability and patient factors.